|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations are early events in the development of IDH-mutant gliomas and leukemias and are associated with various regulation of molecular process.
|
31208797 |
2019 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings supported initiation of the ongoing clinical trials of AG-221 in patients with <i>IDH2</i> mutation-positive advanced hematologic malignancies.<b>Significance:</b> Mutations in <i>IDH1/2</i> are identified in approximately 20% of patients with AML and contribute to leukemia via a block in hematopoietic cell differentiation.
|
28193778 |
2017 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We extensively validate a SL interaction identified by MiSL between the IDH1 mutation and ACACA in leukaemia using gene targeting and patient-derived xenografts.
|
28561042 |
2017 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic gain-of-function mutations in IDH1 and IDH2 confer a neomorphic activity that allow reduction of α -KG to (R)-2- hydroxyglutarate, the accumulation of which results in the development of cancers like low grade gliomas and leukemia.
|
27292784 |
2016 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We show that R-2HG, but not S-2HG or αKG, is an oncometabolite in vivo that does not require the mutant IDH1 protein to induce hyperleukocytosis and to accelerate the onset of murine and human leukemia.
|
27063596 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are found in a subset of benign and malignant cartilage tumors, gliomas and leukaemias.
|
25895133 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.
|
25398939 |
2015 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, somatic IDH1 and IDH2 mutations, and loss-of-function mutations in ten-eleven translocation (TET) methylcytosine dioxygenase-2 (TET2) associated with a hypermethylation phenotype, are also found in multiple enchondromas of patients with Ollier disease and Mafucci syndrome, and leukemia, respectively.
|
23801749 |
2013 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we discuss the relevance of IDH mutations to leukemia pathogenesis, therapy, and outcome and how mutations in IDH1 and IDH2 affect the leukemia epigenome, hematopoietic differentiation, and clinical outcome.
|
23999441 |
2013 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SRSF2 mutations were associated with shortened overall (P < .01) and leukemia-free (P < .01) survival; the adverse effect on survival was independent of DIPSS-plus (P = .01; HR = 1.9; 95% CI, 1.1-3.0) and IDH mutations (P < .01; HR = 2.3; 95% CI, 1.4-3.8).
|
22968464 |
2012 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias.
|
22343896 |
2012 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Miscoding mutations of the TET2 gene, which encodes the α-ketoglutarate-dependent enzyme that catalyses the conversion of 5-methylcytosine to 5-hydroxymethylcytosine, thus producing DNA demethylation, have been detected in 10-25% of acute myeloid leukaemias lacking IDH1/2 mutations.
|
21690245 |
2011 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatic mutations at residue R132 of isocitrate dehydrogenase 1 (IDH1) were recently discovered in gliomas and leukaemia at a high frequency.
|
20702649 |
2010 |